WEST PHARMACEUTICAL SERVICES INC · Surgical & Medical Instruments & Apparatus

WST

Low riskNext report: Due any day

View price ↗

The short version

A high-quality, profitable business with growing sales.

Going well

Sales up 14% in the latest quarter vs a year ago
Profitable every year for 10 years
Brings in more cash than it spends

Money moves

No insider buying or selling in the last 30 days
Institutions cut 0.8% from their holdings in the quarter ending June 2026 (445 bought, 319 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$394.57+0.6% that day

Company value: $27.8B; Share price times all shares
Price vs profit (P/E): 50.5x; You pay about $51 for each $1 of yearly profit
Price vs sales: 8.3x; Company value is 8.3 times a year of sales
Dividend yield: 0.2%; Yearly dividend as a share of today's price
Cash vs value: 2%; Cash as a share of company value
Debt vs value: 1%; Debt as a share of company value

From WST's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$872.3M+14% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $3.3B, up 12% from the 12 months before. Over 5 years, sales grew about 7.4% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of WST. Starting points are the company's recent numbers.

Sales growth+12% a yearRecently: +12% a yearProfit margin17%Last 12 months: 17.0%P/E at the end40xToday: 50.5x. Many steady companies trade at 12x to 25xShare count change-1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$5.9B

Profit in 5 years$997M

Price these guesses point to$595.70+51% vs $394.57 todayAbout +8.6% a year, before dividends

What today's price needs: with a 17% margin and a 40x P/E, sales would have to grow about 3.1% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

6/7Strong

PassReturn on equity 15%+Earns a lot on the money owners have in the business.16.9%
PassDebt under half of equityNot relying on borrowed money.0.06x equity
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.16.1%
PassProfitable every yearSteady profits, not one good year.10 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$468.9M
PassShare count not growingNot diluting owners. Falling means buybacks.-4.1% in 3 years
MissGross margin 40%+Pricing power: sells for well above what it costs to make.35.9%

Revenue: $3.1B; +6.3% vs prior year
5-year growth: +7.4%/yr; revenue, per year
Total debt: $202.8M; 0.06x equity
Current ratio: 3.02x; short-term assets / bills due

From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.